New study results from immunotherapy based treatment strategies

new study results from immunotherapy based treatment strategies

Again, new study results from immunotherapy based treatment strategies have been published and are promising. First-line treatment combining atezolizumab (Tecentriq) and chemotherapy (carboplatin and etoposide) in patients with extensive-stage small cell lung cancer increased survival compared to chemotherapy alone.

http://www.ascopost.com/News/59020

 

IMpower133: Atezolizumab in Combination With Chemotherapy in Previously Untreated, Extensive-Stage Small Cell Lung Cancer- http://www.ascopost.com/News/59020

Encouraging news for patients with triple negative breast cancer

Encouraging news for patients with triple negative breast cancer

Encouraging news for patients with triple negative breast cancer from a phase III immunotherapy study (IMpassion 130). „The combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) as first-line treatment significantly reduced the risk of disease worsening or death in patients with metastatic or unresectable locally advanced triple-negative breast cancer“.

https://de-de.facebook.com/permalink.php?story_fbid=1869551873137690&id=414100488682843

IMpassion130: Atezolizumab Plus Nab-Paclitaxel in Metastatic or Locally Advanced Triple-Negative Breast Cancer – The ASCO Post

The phase III IMpassion130 study has met its co-primary endpoint of progression-free survival (PFS). Results demonstrated that the combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) as first-line treatment significantly reduced the risk of disease worsening or death in patients with metastatic or unresectable locally advanced triple-negative breast cancer. Overall survival (OS) is encouraging…

http://www.ascopost.com/News/59027